Arkolith/Insider Trading/TALS/Form 4

Requadt Scott

Chief Executive Officer, DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Jul 28, 2022
Net Buying
Open-Market Buys
$37K
Open-Market Sells
$0
Net Open-Market Flow
$37K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 28, 2022Buy(P)3K$4.25$13K469K
Jul 26, 2022Buy(P)6K$4.24$23K466K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-026986) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML